PROCEPT BioRobotics (PRCT) AI Stock Analysis

• Market Cap: $1.93B
• Dividend Yield: N/A
• Average Volume (3M): 1.06M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.31
• Revenue Growth: 55.71%
• EPS Growth: 24.37%
• Country: US
• Employees: 756
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.35
• Shares Outstanding: 55,635,940
• 10 Day Avg. Volume: 1,113,478
• 30 Day Avg. Volume: 1,055,597
• PEG Ratio: 2.10
• Price to Book (P/B): 10.43
• Price to Sales (P/S): 18.70
• P/FCF Ratio: -40.50
• Enterprise Value/Market Cap: 1.54
• Enterprise Value/Revenue: 10.80
• Enterprise Value/Gross Profit: 16.83
• Enterprise Value/Ebitda: -36.68
• 1Y Price Target: $62.14
• Price Target Upside: 77.59% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 51 Neutral
• Price Target: $35.00 ▲(0.03% Upside)

PROCEPT BioRobotics shows strong revenue growth and positive future guidance, which are significant strengths. However, ongoing profitability challenges, negative cash flow, and bearish technical indicators weigh heavily on the overall score. The positive sentiment from the earnings call provides some optimism, but valuation concerns and leadership changes pose risks.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for PROCEPT's products, enhancing market position and supporting long-term business sustainability.

Gross Margin Expansion

Improved gross margins reflect operational efficiency and pricing power, contributing to better profitability prospects over time.

Medicare Reimbursement Update

The new Medicare reimbursement code enhances the financial viability of Aquablation therapy, potentially increasing adoption and revenue.

Negative Factors

Profitability Challenges

Ongoing net losses highlight profitability challenges, which could strain financial resources and delay value creation for shareholders.

Negative Cash Flow

Negative cash flow indicates liquidity issues, potentially impacting the company's ability to invest in growth and meet financial obligations.

Leadership Changes

Leadership changes can disrupt strategic direction and execution, potentially affecting the company's market positioning and growth initiatives.

PROCEPT BioRobotics Business Overview & Revenue Model

Company Description

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.

How the Company Makes Money

PROCEPT BioRobotics generates revenue primarily through the sale of its AQUABEAM Robotic System, which is complemented by disposable instruments and accessories used in surgical procedures. The company typically earns money from the initial sale of the robotic systems, which are sold to hospitals and surgical centers, as well as recurring revenue from the sale of consumable products required for each procedure. Additionally, PROCEPT may engage in partnerships with healthcare providers and institutions to enhance its market reach and implement its technologies in a broader range of healthcare settings, contributing to its overall earnings. These partnerships often facilitate training, adoption, and integration of its systems into clinical practice, thereby driving further sales and increasing the company's revenue base.

PROCEPT BioRobotics Financial Statement Overview

Summary

PROCEPT BioRobotics shows strong revenue growth and a robust equity position, indicative of potential long-term stability. However, persistent operating losses and negative cash flows highlight ongoing challenges in profitability and cash management. Continued focus on reducing operational costs and improving cash flow is essential for future sustainability.

Income Statement

The company exhibits strong revenue growth with a TTM increase of 10.96% from the previous year. However, it is still operating at a loss with a negative net profit margin of -36.20% and negative EBIT and EBITDA margins, indicating challenges in achieving profitability. The gross profit margin of 62.19% suggests good product pricing but is offset by high operating expenses.

Balance Sheet

The balance sheet shows a healthy equity position with a substantial equity ratio of 74.93%, indicating low leverage and strong capital structure. The debt-to-equity ratio is 0.20, reflecting modest debt levels compared to equity, which enhances financial stability. However, the company has not yet achieved positive returns on equity due to ongoing net losses.

Cash Flow

The company has a negative free cash flow, although there is a slight improvement with a growth rate of 14.74% in TTM. Operating cash flow remains negative and the operating cash flow to net income ratio is unfavorable, indicating ongoing cash flow challenges. Despite these issues, the company secured significant financing, enhancing liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	274.95M	224.50M	136.19M	75.01M	34.47M	7.72M
Gross Profit	176.49M	137.10M	71.05M	37.09M	15.87M	-1.25M
EBITDA	-80.99M	-82.00M	-98.09M	-77.65M	-51.06M	-45.05M
Net Income	-84.14M	-91.41M	-105.90M	-93.58M	-62.38M	-58.26M
Balance Sheet
Total Assets	513.05M	534.02M	404.72M	309.33M	337.02M	125.97M
Cash, Cash Equivalents and Short-Term Investments	302.72M	333.73M	257.22M	221.86M	304.32M	100.13M
Total Debt	79.37M	80.25M	79.20M	77.32M	54.10M	54.76M
Total Liabilities	127.26M	131.80M	123.97M	112.26M	69.93M	308.87M
Stockholders Equity	385.80M	402.22M	280.75M	197.07M	267.09M	-182.89M
Cash Flow
Free Cash Flow	-89.27M	-103.62M	-133.21M	-83.03M	-57.93M	-48.58M
Operating Cash Flow	-83.21M	-99.21M	-108.00M	-80.38M	-57.33M	-48.34M
Investing Cash Flow	-6.06M	-4.41M	-25.21M	-2.65M	-592.00K	-233.00K
Financing Cash Flow	177.92M	180.13M	167.79M	3.61M	262.12M	106.77M

PROCEPT BioRobotics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 34.99
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRCT, the sentiment is Neutral. The current price of 34.99 is above the 20-day moving average (MA) of 34.58, below the 50-day MA of 37.24, and below the 200-day MA of 54.00, indicating a neutral trend. The MACD of -0.94 indicates Negative momentum. The RSI at 46.59 is Neutral, neither overbought nor oversold. The STOCH value of 60.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PRCT.

PROCEPT BioRobotics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INSP	67 Neutral	$2.41B	46.44	8.07%	―	22.05%	785.52%
LIVN	55 Neutral	$2.97B	―	-17.87%	―	8.57%	-1154.64%
AORT	53 Neutral	$2.05B	―	-5.01%	―	7.44%	-109.83%
ATEC	52 Neutral	$2.35B	―	-376.89%	―	26.27%	15.58%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRCT	51 Neutral	$1.93B	―	-26.40%	―	55.71%	24.37%
SSII	48 Neutral	$1.79B	―	-39.11%	―	135.60%	66.47%

PROCEPT BioRobotics Corporate Events

PROCEPT BioRobotics Updates Executive Severance Agreements

On September 15, 2025, PROCEPT BioRobotics Corporation’s Compensation Committee approved modifications to the Change of Control and Severance Agreement for executive officers below the CEO level. These changes include extending the severance period, clarifying performance-based award accelerations, and altering cash payment timings, aiming to better align executive compensation with market standards.

The most recent analyst rating on (PRCT) stock is a Hold with a $39.00 price target. To see the full list of analyst forecasts on PROCEPT BioRobotics stock, see the PRCT Stock Forecast page.

Procept Biorobotics Reports Strong Q2 Growth Amid Challenges

Procept Biorobotics Corp. recently held its earnings call, revealing a generally positive sentiment. The company reported strong revenue growth, increased handpiece sales, improved gross margins, and favorable Medicare updates, all of which indicate positive operational momentum. Despite challenges such as the timing of system sales, increased operating expenses, continued net loss, and leadership transitions, the overall sentiment remains optimistic due to significant achievements and potential for future growth.

Procept Biorobotics Corp.’s Aquablation Therapy: A Promising Update for Prostate Cancer Treatment

The clinical study titled ‘PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs’ aims to evaluate the performance and safety of the AQUABEAM Robotic System. This system is used for the resection and removal of prostate tissue in patients with lower urinary tract symptoms and localized prostate cancer. The study’s significance lies in its potential to offer a minimally invasive treatment option, improving patient outcomes and quality of life.

PROCEPT BioRobotics Reports Strong Q2 2025 Growth

PROCEPT BioRobotics Corporation, a surgical robotics company specializing in urology, is known for its innovative solutions like Aquablation therapy, which aims to improve patient care and outcomes in the treatment of benign prostatic hyperplasia (BPH).

PROCEPT BioRobotics Appoints New CEO Larry L. Wood

On July 23, 2025, PROCEPT BioRobotics announced the appointment of Larry L. Wood as President and CEO, effective September 2, 2025, succeeding Dr. Reza Zadno, who will retire on September 1, 2025. Dr. Zadno will transition to a consulting role, having led the company through significant growth, including the adoption of Aquablation therapy and a successful public offering. Mr. Wood, with over 40 years of experience in the medical technology industry, joins from Edwards Lifesciences and has been a member of PROCEPT BioRobotics’ board since 2024. The company also pre-announced second-quarter 2025 revenue of approximately $79.2 million, representing an annual growth of 48%.

The most recent analyst rating on (PRCT) stock is a Buy with a $99.00 price target. To see the full list of analyst forecasts on PROCEPT BioRobotics stock, see the PRCT Stock Forecast page.